Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628542 | 0.88 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628900 | 0.85 | HTR1A (0.78) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6627159 | 0.85 | HTR1A (0.73) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628788 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5767215 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6796482 | 0.84 | HTR1A (0.75) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6626528 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628586 | 0.84 | HTR1A (0.76) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628786 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5844673 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800641-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | claimed |
| US-6800641-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088133-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-2,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | SNCA, SYNJ1, SLC6A3 | HTR1A 86/4885SLC6A4 549/4885KDM4E 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.